Morgan Stanley Tarsus Pharmaceuticals, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,012,777 shares of TARS stock, worth $87.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,012,777

Previous 1,969,071 2.22%

Holding current value

$87.4 Million

Previous $109 Million 5.16%

% of portfolio

0.01%

Previous 0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2025 May 15, 2025	BUY	$41.29 - $56.94 $1.8 Million - $2.49 Million	43,706 Added 2.22%	2,012,777 $103 Million
Q4 2024 Feb 14, 2025	SELL	$32.27 - $55.37 $7.73 Million - $13.3 Million	-239,517 Reduced 10.84%	1,969,071 $109 Million
Q3 2024 May 14, 2025	BUY	$21.54 - $34.6 $6.98 Million - $11.2 Million	323,903 Added 17.19%	2,208,588 $72.6 Million
Q3 2024 Nov 14, 2024	BUY	$21.54 - $34.6 $6.98 Million - $11.2 Million	323,903 Added 17.19%	2,208,588 $72.6 Million
Q2 2024 May 14, 2025	SELL	$25.17 - $38.73 $2.12 Million - $3.27 Million	-84,386 Reduced 4.29%	1,884,685 $51.2 Million
Q2 2024 Oct 17, 2024	SELL	$25.17 - $38.73 $12.9 Million - $19.9 Million	-514,233 Reduced 21.44%	1,884,685 $51.2 Million
Q2 2024 Aug 14, 2024	SELL	$25.17 - $38.73 $12.9 Million - $19.9 Million	-514,233 Reduced 21.44%	1,884,685 $51.2 Million
Q1 2024 Oct 17, 2024	BUY	$19.61 - $39.22 $10.1 Million - $20.2 Million	514,233 Added 27.28%	2,398,918 $87.2 Million
Q1 2024 Aug 16, 2024	BUY	$19.61 - $39.22 $8.65 Million - $17.3 Million	441,230 Added 22.54%	2,398,918 $87.2 Million
Q1 2024 May 15, 2024	BUY	$19.61 - $39.22 $8.65 Million - $17.3 Million	441,230 Added 22.54%	2,398,918 $87.2 Million
Q4 2023 Aug 16, 2024	BUY	$12.98 - $20.73 $947,578 - $1.51 Million	73,003 Added 3.87%	1,957,688 $39.6 Million
Q4 2023 Feb 13, 2024	BUY	$12.98 - $20.73 $24.5 Million - $39.1 Million	1,883,869 Added 2552.01%	1,957,688 $39.6 Million
Q3 2023 Nov 15, 2023	BUY	$14.75 - $24.62 $350,135 - $584,429	23,738 Added 47.4%	73,819 $1.31 Million
Q2 2023 Aug 14, 2023	BUY	$11.57 - $19.63 $206,941 - $351,102	17,886 Added 55.56%	50,081 $904,000
Q1 2023 May 15, 2023	BUY	$11.92 - $16.27 $87,468 - $119,389	7,338 Added 29.52%	32,195 $404,000
Q4 2022 Feb 14, 2023	BUY	$14.12 - $18.72 $8,288 - $10,988	587 Added 2.42%	24,857 $364,000
Q3 2022 Nov 14, 2022	SELL	$14.08 - $18.5 $152,753 - $200,706	-10,849 Reduced 30.89%	24,270 $416,000
Q2 2022 Oct 27, 2022	BUY	$11.08 - $19.08 $264,900 - $456,164	23,908 Added 213.25%	35,119 $512,000
Q2 2022 Aug 15, 2022	BUY	$11.08 - $19.08 $264,900 - $456,164	23,908 Added 213.25%	35,119 $512,000
Q1 2022 Oct 27, 2022	SELL	$14.49 - $24.28 $346,426 - $580,486	-23,908 Reduced 68.08%	11,211 $188,000
Q1 2022 May 13, 2022	SELL	$14.49 - $24.28 $391 - $655	-27 Reduced 0.24%	11,211 $188,000
Q4 2021 Feb 14, 2022	SELL	$21.21 - $29.68 $366,763 - $513,226	-17,292 Reduced 60.61%	11,238 $253,000
Q3 2021 Nov 15, 2021	BUY	$21.45 - $29.22 $611,968 - $833,646	28,530 New	28,530 $615,000

Others Institutions Holding TARS

# of Institutions

200

Shares Held

44.5M

Call Options Held

19.9K

Put Options Held

7.6K

View Full List

About Tarsus Pharmaceuticals, Inc.

Ticker TARS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,658,500
Market Cap $1.16B
Description
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...

More about TARS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account